Eli Lilly was hoping for even greater weight loss drug demand
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Ozempic 3.0? This drug causes the greatest weight loss — by far
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective for obese adults who do not have diabetes.
New Weight Loss Drugs May Fight Obesity-Related Cancer, Too
Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.
Lilly sues two medical spas over copycat weight-loss drugs
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound. The new lawsuits name Thrive Health and Wellness LLC and Valhalla Vitality LLC.
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Lilly asks to join lawsuit over compounded versions of its weight-loss drugs
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump
Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down more than 8% on Tuesday.
Eli Lilly's weight loss pill could get federal approval by early next year
Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks told Bloomberg News on Monday that data on the drug, orforglipron, is expected before the middle of 2025.
Medicine Buffalo22h
UB pharmacy professor discusses pros and cons of popular weight-loss drugs
Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...
Some GLP-1s Achieve More Weight Loss Than Others: Study
However, a third drug also FDA-approved for weight loss, liraglutide (Saxenda), didn’t work as well as the others, ...
HeraldNet4d
Zest Meds: Semaglutide and Tirzepatide Treatments Changing the Weight Loss Game?
Zest Meds is more than just a healthcare provider; it’s a partner in your weight loss journey. Specializing in cutting-edge treatments like Semaglutide and Tirzepatide, Zest Meds has positioned ...
krcgtv.com5d
Weight loss options to help New Year's resolutions include GLP-1 injections
The New Year is a time of reflection and change for many Americans, who start each January with a clean slate and goals for ...
Hosted on MSN14h
How Ozempic, Zepbound, and Mounjaro will transform India's weight loss market
The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...